COMP <GO>
CENX vs TMO // ALTMAN Z-SCORE & DEBT/EQUITY
Century Aluminum Company (NASDAQ) VS. Thermo Fisher Scientific Inc (NYSE) • 15-METRIC TALLY: CENX 5
— TMO 10
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: TMO
LAST: $33.70 (-2.74%) • MKT CAP: $3.43B
balance-sheet
2.50
LAST: $697.00 (-1.72%) • MKT CAP: $262.22B
balance-sheet
4.50
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CENX VS. TMO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CENX | TMO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 10.10% | 41.00% | -30.90 | TMO | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 11.10% | 9.30% | +1.80 | CENX | /roic <GO> |
| EV/EBITDA & P/E Valuation | 15.4x | 30.4x | -15.00 | CENX | /valuation <GO> |
| Free Cash Flow Yield | 2.47% | 2.40% | +0.07 | CENX | /fcf-yield <GO> |
| Operating Margin | 6.30% | 17.40% | -11.10 | TMO | /operating-margins <GO> |
| Net Profit Margin | 1.60% | 15.10% | -13.50 | TMO | /net-margins <GO> |
| Revenue Growth (YoY) | 13.90% | 3.90% | +10.00 | CENX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.24% | -0.24 | TMO | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 2.50 | 4.50 | -2.00 | TMO | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 8/9 | -1.00 | TMO | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.20% | 6.70% | +0.50 | TMO | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 42.5 | 59.1 | -16.63 | TMO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.10 | 0.94 | +0.16 | CENX | /macro-sensitivity <GO> |
| Forward P/E Multiple | 72.1x | 36.3x | +35.80 | TMO | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.43B | $262.22B | -$258.79B | TMO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CENX REV | TMO REV | CENX GROSS % | TMO GROSS % | CENX FCF | TMO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.53B | $44.56B | 10.1% | 44.0% | $84.8M | $6.29B |
| FY 2024 | $2.22B | $42.88B | 7.7% | 44.0% | -$106.9M | $7.27B |
| FY 2023 | $2.19B | $42.86B | 44.0% | 44.0% | $7.3M | $6.48B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CENX // BETA 1.10
TMO // BETA 0.94